ALLN 346
Alternative Names: ALLN-346; Engineered urate oxidaseLatest Information Update: 28 Jan 2025
At a glance
- Originator Allena Pharmaceuticals
- Class Antigouts; Enzymes; Oxidoreductases; Uricosurics; Urologics
- Mechanism of Action Urate oxidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gout; Hyperuricaemia; Renal failure
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in Gout(In volunteers) in United Kingdom (PO, Capsule)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Hyperuricaemia(In volunteers) in United Kingdom (PO, Capsule)
- 23 Jun 2023 Allena Pharmaceuticals terminates a phase II clinical trials in Renal failure (In adults, In the elderly) due to company financing in USA (PO) (NCT04987294)